Characterization of an in vitro cell culture bioreactor system to evaluate anti-neoplastic drug regimens

被引:13
作者
Kirstein, MN
Brundage, RC
Elmquist, WF
Remmel, RP
Marker, PH
Guire, DE
Yee, D
机构
[1] Univ Minnesota, Dept Expt & Clin Pharmacol, Coll Pharm, Minneapolis, MN 55455 USA
[2] Univ Minnesota, Ctr Comprehens Canc, Minneapolis, MN 55455 USA
[3] Univ Minnesota, Dept Pharmaceut, Coll Pharm, Minneapolis, MN 55455 USA
[4] Univ Minnesota, Dept Med Chem, Coll Pharm, Minneapolis, MN 55455 USA
[5] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA
[6] Univ Minnesota, Stem Cell Inst, Minneapolis, MN 55455 USA
[7] Univ Minnesota, Ctr Canc, Minneapolis, MN 55455 USA
关键词
bioreactor; Gemcitabine; in vitro; MDA-231; cells; pharmacokinetics; S-phase;
D O I
10.1007/s10549-005-9004-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A dynamic 3-dimensional tissue culture system has been developed that will allow for control of gemcitabine exposure to mimic concentration-time profiles measured from biologic samples. Gemcitabine was infused into a central reservoir. Media is mixed and delivered through hollow fiber capillaries, where it diffuses into the extracapillary space containing anchorage-dependent MDA-231 cells. To test for control of gemcitabine concentration-time profiles, drug was first infused through bioreactors without cells, and gemcitabine concentrations were measured with HPLC. Concentrations could be controlled to simulate 30-min and 2.5 h infusions, and were similar in both the lumen and extracapillary space. MDA-231 cells were then seeded into control (n = 4) and gemcitabine treatment (n = 4) groups, and maintained in culture for 2 weeks. Gemcitabine (5.3 mg) was infused over 30 min to the treatment group, and blank media to the control group. Accuracy of measured gemcitabine maximum concentration (C-max) was 83.4%, and area under the curve (AUC), 106.2%, relative to pre-experimental theoretical values. With cells present, gemcitabine AUC in the extracapillary space was 32% of the value in the lumen. For the control group, 21.2 million cells (94.3% viable) were recovered, and for the gemcitabine-treated group, 16.8 million cells (87.1 % viable). Flow cytometry showed that 13.3 % of cells in the control group were in S-phase and 34.3 % in the gemcitabine-treated group were in S-phase (p = 0.003). In conclusion, gemcitabine concentration-time profiles could be accurately controlled through dosage, infusion rate, and pump flow rate, and cells could be recovered afterward to evaluate drug treatment.
引用
收藏
页码:217 / 225
页数:9
相关论文
共 40 条
[1]   A PHASE-I CLINICAL, PLASMA, AND CELLULAR PHARMACOLOGY STUDY OF GEMCITABINE [J].
ABBRUZZESE, JL ;
GRUNEWALD, R ;
WEEKS, EA ;
GRAVEL, D ;
ADAMS, T ;
NOWAK, B ;
MINEISHI, S ;
TARASSOFF, P ;
SATTERLEE, W ;
RABER, MN ;
PLUNKETT, W .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (03) :491-498
[2]   Sequence dependent potentiation of gemcitabine by flavopiridol in human breast cancer cells [J].
Ali, S ;
El-Rayes, BF ;
Aranha, O ;
Sarkar, FH ;
Philip, PA .
BREAST CANCER RESEARCH AND TREATMENT, 2005, 90 (01) :25-31
[3]   EFFECT OF 2',3'-DIDEHYDRO-3'-DEOXYTHYMIDINE IN AN IN-VITRO HOLLOW-FIBER PHARMACODYNAMIC MODEL SYSTEM CORRELATES WITH RESULTS OF DOSE-RANGING CLINICAL-STUDIES [J].
BILELLO, JA ;
BAUER, G ;
DUDLEY, MN ;
COLE, GA ;
DRUSANO, GL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (06) :1386-1391
[4]   KINETIC-STUDIES ON 2',2'-DIFLUORODEOXYCYTIDINE (GEMCITABINE) WITH PURIFIED HUMAN DEOXYCYTIDINE KINASE AND CYTIDINE DEAMINASE [J].
BOUFFARD, DY ;
LALIBERTE, J ;
MOMPARLER, RL .
BIOCHEMICAL PHARMACOLOGY, 1993, 45 (09) :1857-1861
[5]   Phase I trial of combined-modality therapy for localized esophageal cancer: Escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy [J].
Brenner, B ;
Ilson, DH ;
Minsky, BD ;
Bains, MS ;
Tong, W ;
Gonen, M ;
Kelsen, DP .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (01) :45-52
[6]   Cell cycle effects of gemcitabine [J].
Cappella, P ;
Tomasoni, D ;
Faretta, M ;
Lupi, M ;
Montalenti, F ;
Viale, F ;
Banzato, F ;
D'Incalci, M ;
Ubezio, P .
INTERNATIONAL JOURNAL OF CANCER, 2001, 93 (03) :401-408
[7]   Caspase-3 drives apoptosis in pancreatic cancer cells after treatment with gemcitabine [J].
Chandler, NM ;
Canete, JJ ;
Callery, MP .
JOURNAL OF GASTROINTESTINAL SURGERY, 2004, 8 (08) :1072-1078
[8]   COMPUTERIZED QUANTITATION OF SYNERGISM AND ANTAGONISM OF TAXOL, TOPOTECAN, AND CISPLATIN AGAINST HUMAN TERATOCARCINOMA CELL-GROWTH - A RATIONAL APPROACH TO CLINICAL PROTOCOL DESIGN [J].
CHOU, TC ;
MOTZER, RJ ;
TONG, YZ ;
BOSL, GJ .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (20) :1517-1524
[9]   QUANTITATIVE-ANALYSIS OF DOSE-EFFECT RELATIONSHIPS - THE COMBINED EFFECTS OF MULTIPLE-DRUGS OR ENZYME-INHIBITORS [J].
CHOU, TC ;
TALALAY, P .
ADVANCES IN ENZYME REGULATION, 1984, 22 :27-55
[10]   A RANDOMIZED TRIAL OF 2 ETOPOSIDE SCHEDULES IN SMALL-CELL LUNG-CANCER - THE INFLUENCE OF PHARMACOKINETICS ON EFFICACY AND TOXICITY [J].
CLARK, PI ;
SLEVIN, ML ;
JOEL, SP ;
OSBORNE, RJ ;
TALBOT, DI ;
JOHNSON, PWM ;
REZNEK, R ;
MASUD, T ;
GREGORY, W ;
WRIGLEY, PFM .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (07) :1427-1435